Medindia LOGIN REGISTER
Medindia
Advertisement

Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting

Wednesday, November 19, 2008 General News
Advertisement
LONDON, November 19 NeuroDiscovery Ltd (ASX:NDL), a specialty neuroscience service provider and drug development Company,and Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), a leadinginternational biopharmaceutical company, today announce that NeuroSolutionsis presenting further pivotal pre-clinical efficacy data for NSL-043/SD118.This investigational drug is a potential therapy for neuropathic pain and hassuccessfully completed Phase I clinical studies and is now ready for Phase IIstudies.
Advertisement

The data presented demonstrate that NSL-043/SD-118 reverses staticallodynia and inhibits spontaneous ectopic discharge in thestreptozotocin-induced diabetic neuropathy and chronic constriction injurymodels of neuropathic hypersensitivity and suggest that this compound may beeffective in treating neuropathic pain in man.
Advertisement

NSL-043/SD118 is being jointly developed by NeuroDiscovery and its whollyowned subsidiary NeuroSolutions Ltd under a collaboration agreement withSosei concluded in June 2006. NSL-043/SD118 was previously under clinicalinvestigation in Japan for a different indication and demonstrated apotential new use as an oral therapy in neuropathic pain through are-profiling collaboration.

Dr Chris Moyses, Group Chief Executive of NeuroDiscovery, commented: "Weare delighted to announce these important observations which represent avaluable endorsement of the Company's approach to discovering first-in-classcompounds that are clearly differentiated from existing therapeutics used inthe management of neuropathic and inflammatory pain."

Mr Shinichi Tamura, CEO Sosei Group added: "We are pleased to havecollaborated with NeuroDiscovery on this project and to have generated aclinical asset in an area of significant unmet medical need."

Neuroscience 2008, the Society for Neuroscience's 38th annual meeting, isscheduled for Nov. 15 to 19 in Washington, DC. Each year SfN provides thepremier venue for neuroscientists to share research findings. SfN's annualmeeting draws diverse attendees from all over the world.

About NeuroDiscovery

NeuroDiscovery Ltd is an ASX listed speciality neuroscience servicesprovider and drug development company which owns 100% of NeuroSolutions Ltd(ASX Code NDL).

About NeuroSolutions

NeuroSolutions Limited is a profitable service company, which has appliedits broad spectrum expertise and drug discovery platforms to become a leadingprovider of specialised electrophysiological assays to the biopharmaceuticalindustry. Electrophysiology is a specialised technique which is used torecord electrical activity in membranes, cells or tissues. NeuroSolutions'current clients include many established pharmaceutical and biotechnologycompanies.

In parallel to running its service business, the Company is alsoexploiting its in-house technologies and expertise for its own internal R&Dand has a mature pipeline of programmes underway for the treatment of pain.

During 2008, the Company reported success in a Phase II trial forNSL-101. The Company also successfully completed two Phase I trials for thedevelopment compound NSL-043/SD118, in partnership with Sosei Co. Ltd. Bothof these trials reported a successful outcome, facilitating furtherdevelopment.

About Sosei

Sosei Group is a leading international biopharmaceutical company withsignificant expertise in product discovery and development. It hasestablished a reduced risk business model primarily upon identifying new usesfor established drugs and exploiting its unique position within Japanese,European and North American pharmaceutical markets by acquiring compoundsfrom, and bringing compounds into, Japan.

For further information about Sosei, please visit http://www.sosei.com

Except for historical information, this news release may containforward-looking statements that reflect the Company's current expectationregarding future events. These forward looking statements involve risk anduncertainties, which may cause but are not limited to, changing marketconditions, the successful and timely completion of clinical studies, theestablishment of corporate alliances, the impact of competitive products andpricing, new product development, uncertainties related to the regulatoryapproval process, and other risks detailed from time to time in the Company'songoing quarterly and annual reporting.

SOURCE Sosei Group Corporation
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close